All In MedTech

Device Trial Radar · NCT07929857

Effectiveness and Safety of Cellbooster Hair in Healthy Subjects

A Prospective, Open Study on the Safety and Effectiveness of CellBooster® Hair

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Jan 27, 2027

Primary completion

Oct 31, 2027

Study completion Oct 31, 2027

Sponsor

Lead sponsor
SuisselleNot on our public-company list
Sponsor type
Industry
First posted
Nov 10, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Cellbooster® Hair (CBH) is a class III medical device, CE marked, HA-based injectable using the patented CHAC Technology. It consists of stabilized Hyaluronic Acid 18mg (6mg/ml) with Amino Acids and Vitamins, and minerals (zinc, copper). The medical device is designed for strengthening hair follicles, improving hair growth and microcirculation. It restores scalp skin structure and provides hair fiber restructuring. The device is a resorbable injectable implant for preventing and treating various scalp and hair problems linked to hormonal imbalance, psoriasis, seborrhea, stress, nutrition and trace elements deficiencies, such as: hair loss, hair breakage, scalp dehydration, dandruff, premature graying. The device improves microcirculation, restores scalp skin structure and other qualities, provides hair fiber restructuring after physical and/or chemical damage, such as: hair dying, permanent wave, sun, dryer. The current post-market clinical investigation aims to evaluate the efficacy and safety of CBH in the scalp of subjects. For this purpose, healthy subjects with signs of hair loss will receive a 6-session treatment spaced every 2 weeks and will be followed-up over 130 days after the initial injection session. Objective measurements of scalp function and hair characteristics parameters will be performed allowing to assess hair density, hair diameter, hair structure, scalp hydration, scalp barrier function and thickness and having illustrative pictures. Subjective clinical improvement will be evaluated with clinical scoring, as well as subject and investigator satisfaction degrees. The safety of the injections will be assessed by collecting the Injection Site Reactions (ISRs) and Adverse Events (AEs).

Conditions

  • Hair and Scalp Health

Interventions

  • Scalp booster injection (CBH)Device

    Eligible subjects will receive six intradermal treatment sessions with CBH, administered at 14-day intervals on Days 0, 14, 28, 42, 56 and 70. CellBooster® Hair (CBH) Class III medical device Composition non-crosslinked Sodium Hyaluronate 18 mg; * amino acids (Arginine, Cysteine, Glutamine, Glycine, Lysine); * vitamins (Niacin, Pantothenic Acid, Pyridoxine, Biotin, Cyanocobalamin, Rutin); * Copper Gluconate, Zinc Carbonate; * phosphate buffer pH 6.8-7.6 q.s.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline of hair density (total number of hair in the studied zone) at Day 130 evaluated by Phototrichogram (PTG) analysisTime frame: Day 130

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Eurofins Dermscan Pharmascan

    Aix-en-Provence, France

  • Eurofins Dermscan Pharmascan

    Villeurbanne, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.